Captor Therapeutics SA (CTXP)

Currency in PLN
79.00
+1.00(+1.28%)
Delayed Data·
CTXP is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
77.8079.00
52 wk Range
31.2086.00
Key Statistics
Bid/Ask
78.20 / 79.40
Prev. Close
78
Open
78
Day's Range
77.8-79
52 wk Range
31.2-86
Volume
819
Average Volume (3m)
12.88K
1-Year Change
53.1008%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
CTXP Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
98.13
Upside
+24.22%
Members' Sentiments
Bearish
Bullish
ProTips
Analysts do not anticipate the company will be profitable this year

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Buy
Moving Averages
Strong Buy

Captor Therapeutics Company Profile

Captor Therapeutics Spolka Akcyjna, a biopharmaceutical company, focuses on the discovery and development of protein degradation drugs for cancer and autoimmune diseases. The company provides Targeted Protein Degradation technology that overcomes many existing drug limitations by removing proteins resistant to available therapeutics. Its products in various stages of development include CT-03, which has completed the Phase 1 clinical trials for the treatment of non-small cell lung cancer, triple-negative breast cancer, as well as cancers of the blood, lymphatic system, and bone marrow; and CT-01, which also completed the Phase 1 clinical trials for the treatment of hepatocellular carcinoma, through degradation of oncofetal transcription factor. The company was incorporated in 2015 and is headquartered in Wroclaw, Poland.

Compare CTXP to Peers and Sector

Metrics to compare
CTXP
Peers
Sector
Relationship
P/E Ratio
−10.6x−4.9x−0.5x
PEG Ratio
−1.560.350.00
Price/Book
13.0x3.1x2.6x
Price / LTM Sales
57.0x6.6x3.3x
Upside (Analyst Target)
34.3%42.4%48.1%
Fair Value Upside
Unlock5.4%7.7%Unlock

Analyst Ratings

3 Buy
0 Hold
0 Sell
Ratings:
3 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 98.13
(+24.22% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate

Earnings

Latest Release
Nov 20, 2025
EPS / Forecast
-2.07 / --
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

People Also Watch

9.670
DVLP
-1.12%
47.00
SHO1
-2.89%
42.85
MURP
+0.12%
147.50
BNP1
-0.34%
136.00
VRCP
-3.00%

FAQ

What Is the Captor Therapeutics (CTXP) Share Price Today?

The live Captor Therapeutics share price today is 79.00

What Stock Exchange Does Captor Therapeutics (CTXP) Trade On?

Captor Therapeutics is listed and trades on the Warsaw Stock Exchange.

What Is the Ticker (Stock Symbol) for Captor Therapeutics?

The stock symbol (also called a 'ticker') for Captor Therapeutics is "CTXP."

What Is the Current Captor Therapeutics Market Cap?

As of today, Captor Therapeutics market capitalisation is 431.24M.

What Is Captor Therapeutics's (CTXP) Earnings Per Share (TTM)?

The Captor Therapeutics EPS is currently -7.69 (Trailing Twelve Months).

When Is the Next Captor Therapeutics Earnings Date?

Captor Therapeutics's next earnings report will be released on 01 Apr 2026.

Is CTXP a Buy or Sell From a Technical Analyst Perspective?

Based on today's Captor Therapeutics moving averages and other technical indicators, the daily buy/sell signal is Neutral.

How Many Times Has Captor Therapeutics Stock Split?

Captor Therapeutics has split 0 times. (See the CTXP stock split history page for full effective split date and price information.)

How Many Employees Does Captor Therapeutics Have?

Captor Therapeutics has 91 employees.

What is the current trading status of Captor Therapeutics (CTXP)?

As of 06 Feb 2026, Captor Therapeutics (CTXP) is trading at a price of 79.00, with a previous close of 78.00. The stock has fluctuated within a day range of 77.80 to 79.00, while its 52-week range spans from 31.20 to 86.00.

What Is Captor Therapeutics (CTXP) Price Target According to Analysts?

The average 12-month price target for Captor Therapeutics is PLN98.13, with a high estimate of PLN122.4 and a low estimate of PLN67. 3 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +24.22% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.